NEPH
BEARISH
$2.88
Live
Nephros, Inc. · NASDAQ
Target $7.0
(+143.1%)
$1.64
52W Range
$6.42
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 15, 2026
Market cap
$30.66M
P/E
26.18
ROE
12.7%
Profit margin
6.4%
Debt/Equity
0.1
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
NEPH presents a contradictory profile with a stable Piotroski F-Score of 4/9 and a very strong balance sheet, yet it is fundamentally overvalued. The current price of $2.88 significantly exceeds both the Graham Number ($1.54) and the Intrinsic Value ($0.77), suggesting a speculative premium. While revenue growth remains positive at 22.2%, the catastrophic collapse in earnings growth (-82.40% YoY) and a bearish technical trend (0/100) outweigh the analyst target of $7.00.
Key Strengths
Very low leverage with a Debt/Equity ratio of 0.10
Excellent short-term liquidity (Current Ratio 4.06)
Strong Gross Margins at 61.87%
Consistent positive revenue growth (22.20% YoY)
Positive ROE of 12.71% indicating efficient equity use
Key Risks
Severe earnings contraction (-82.40% YoY)
Significant overvaluation relative to Graham and Intrinsic value models
Razor-thin operating margins (0.38%) indicating high overhead
Strong bearish technical momentum (0/100 trend score)
Micro-cap volatility and low market capitalization ($0.03B)
AI Fair Value Estimate
Based on comprehensive analysis
$1.65
-42.7% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
37
Weak
30
45
35
75
0
AI Verdict
Speculative/Overvalued
Key drivers: Balance sheet strength, Earnings collapse, Valuation gap
Confidence
80%
Value
30/100
Ref P/E 26.18, Graham Number $1.54
Positives
- P/S ratio is relatively low at 1.63
Watchpoints
- Price is 86% above Graham Number
- Price is 272% above Intrinsic Value
Future
45/100
Ref Growth rates
Positives
- Revenue growth of 22.20%
Watchpoints
- Earnings growth plummeted by 82.40%
- Negative Q/Q EPS growth
Past
35/100
Ref Historical trends
Positives
- Recent 1Y return of +42.6%
Watchpoints
- 5Y change is -63.0%
- Recent 6M decline of -46.5%
Health
75/100
Ref Piotroski F-Score 4/9, Debt/Equity 0.10
Positives
- Very low Debt/Equity
- High Current and Quick ratios
Watchpoints
- Piotroski F-Score is only 4/9 (Stable, not Strong)
Dividend
0/100
Ref Yield N/A
Positives
No standout positives identified.
Watchpoints
- No dividend payments
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$2.88
Analyst Target
$7.0
Upside/Downside
+143.1%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for NEPH and closest competitors.
Updated 2026-04-14
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
NEPH
Nephros, Inc.
Primary
|
-63.0% | +102.8% | +42.6% | -46.5% | -1.4% | +3.6% |
|
EKSO
Ekso Bionics Holdings, Inc.
Peer
|
-91.1% | -64.0% | +54.0% | +66.6% | -27.2% | -18.0% |
|
BTAI
BioXcel Therapeutics, Inc.
Peer
|
-99.8% | -99.6% | -30.1% | -56.4% | -37.0% | -18.7% |
|
KYNB
Kyntra Bio, Inc.
Peer
|
-98.6% | -98.5% | +10.3% | -32.0% | +0.7% | +2.3% |
|
AYTU
Aytu BioPharma, Inc.
Peer
|
-98.4% | -24.2% | +61.7% | +2.7% | +6.7% | +1.5% |
NEP
Nephros, Inc.
Primary
5Y
-63.0%
3Y
+102.8%
1Y
+42.6%
6M
-46.5%
1M
-1.4%
1W
+3.6%
EKS
Ekso Bionics Holdings, Inc.
Peer
5Y
-91.1%
3Y
-64.0%
1Y
+54.0%
6M
+66.6%
1M
-27.2%
1W
-18.0%
BTA
BioXcel Therapeutics, Inc.
Peer
5Y
-99.8%
3Y
-99.6%
1Y
-30.1%
6M
-56.4%
1M
-37.0%
1W
-18.7%
KYN
Kyntra Bio, Inc.
Peer
5Y
-98.6%
3Y
-98.5%
1Y
+10.3%
6M
-32.0%
1M
+0.7%
1W
+2.3%
AYT
Aytu BioPharma, Inc.
Peer
5Y
-98.4%
3Y
-24.2%
1Y
+61.7%
6M
+2.7%
1M
+6.7%
1W
+1.5%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
26.18
Forward P/E
22.15
PEG Ratio
N/A
P/B Ratio
3.01
P/S Ratio
1.63
EV/Revenue
1.4
EV/EBITDA
20.48
Market Cap
$30.66M
Profitability
Profit margins and return metrics
Profit Margin
6.35%
Operating Margin
0.38%
Gross Margin
61.87%
ROE
12.71%
ROA
5.76%
Growth
Revenue and earnings growth rates
Revenue Growth
+22.2%
Earnings Growth
-82.4%
Q/Q Revenue Growth
+22.2%
Q/Q Earnings Growth
-82.2%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.1
Low debt
Current Ratio
4.06
Strong
Quick Ratio
2.82
Excellent
Cash/Share
$0.51
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Gross Margin
58.4%
Op. Margin
0.4%
Net Margin
1.3%
Total Assets
$0.0B
Liabilities
$0.0B
Equity
$0.0B
Debt/Equity
0.34x
Operating CF
$0.0B
Free Cash Flow
$0.0B
FCF Yield
100%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-07
$N/A
2026-03-12
$0.01
2025-11-06
$0.03
+250.0% surprise
2025-08-07
$0.02
+180.0% surprise
Healthcare Sector Comparison
Comparing NEPH against 393 companies in the Healthcare sector
(24 bullish, 129 neutral, 240 bearish)
P/E Ratio
26.18
This Stock
vs
90.61
Sector Avg
-71.1%
(Discount)
Return on Equity (ROE)
12.71%
This Stock
vs
-101.52%
Sector Avg
-112.5%
(Below Avg)
Profit Margin
6.35%
This Stock
vs
-12.47%
Sector Avg
-151.0%
(Weaker)
Debt to Equity
0.1
This Stock
vs
3.4
Sector Avg
-96.9%
(Less Debt)
Revenue Growth
22.2%
This Stock
vs
124.21%
Sector Avg
-82.1%
(Slower)
Current Ratio
4.06
This Stock
vs
4.56
Sector Avg
-11.0%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
NEPH
Nephros, Inc.
|
BEARISH | $30.66M | 26.18 | 12.7% | 6.4% | $2.88 | |
|
EKSO
Ekso Bionics Holdings, Inc.
|
BEARISH | $31.11M | - | -107.6% | -91.4% | $8.73 | Compare |
|
BTAI
BioXcel Therapeutics, Inc.
|
BEARISH | $29.51M | - | -% | -% | $1.09 | Compare |
|
KYNB
Kyntra Bio, Inc.
|
BEARISH | $29.02M | - | -% | 2848.6% | $7.17 | Compare |
|
AYTU
Aytu BioPharma, Inc.
|
NEUTRAL | $27.51M | - | -50.2% | -20.5% | $2.7 | Compare |
NEPH
Nephros, Inc.
BEARISH
Mkt Cap
$31M
P/E
26.2
ROE
12.7%
Price
$2.88
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-23 | KRANDEL JUDITH FINGER | Chief Financial Officer | Option Exercise | 68,861 | $117,752 |
| 2026-03-23 | BANKS ROBERT R JR. | Chief Executive Officer | Option Exercise | 120,000 | $172,800 |
| 2026-03-16 | AMRON ARTHUR H | Director | Stock Award | 3,610 | - |
| 2025-11-10 | AMRON ARTHUR H | Director | Stock Award | 5,391 | - |
| 2025-11-10 | SPANDOW OLIVER J | Director | Stock Award | 8,036 | - |
| 2025-11-10 | NETTIS LISA MARIE | Director | Stock Award | 1,622 | - |
KRANDEL JUDITH FINGER
Chief Financial Officer
2026-03-23
68,861 shares
·
$117,752
BANKS ROBERT R JR.
Chief Executive Officer
2026-03-23
120,000 shares
·
$172,800
AMRON ARTHUR H
Director
2026-03-16
3,610 shares
AMRON ARTHUR H
Director
2025-11-10
5,391 shares
SPANDOW OLIVER J
Director
2025-11-10
8,036 shares
NETTIS LISA MARIE
Director
2025-11-10
1,622 shares
Insider transactions can signal confidence or concerns about company prospects
Past News Coverage
Recent headlines mentioning NEPH from our newsroom.
Newest → oldest
No matching news yet.